newsfilter
← Latest News
ACCESS Newswire·

IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia

  • IGC Pharma received authorization from Colombia's Fondo Nacional de Estupefacientes on April 9, 2026, to synthesize, formulate, & conduct development activities involving psilocybin at its Bogotá facility.
  • The Company is among a limited number of organizations in Colombia holding this specific regulatory capability for psilocybin research.
  • This authorization enables evaluation of psilocybin for neuropsychiatric symptoms associated with dementia, including depression & anxiety, which affect approximately 80% of Alzheimer's patients.
  • IGC Pharma aims to utilize this capital-efficient platform to explore differentiated therapeutic mechanisms beyond its lead candidate, IGC-AD1.
  • The Phase 2 CALMA clinical trial for IGC-AD1, targeting agitation in Alzheimer's disease, has reached approximately 80% patient enrollment & is approaching completion.
  • CEO Ram Mukunda stated that while the CALMA trial remains the primary near-term focus, the Company is building a multi-pronged approach to the Alzheimer's market using this new authorization.